Sinopharm’s inactivated vaccine once morest Covid-19 is “highly protective once morest serious and critical hospitalizations”. This is what emerges from the results of a study conducted between February 1 and June 30, 2021, among 348,190 adults aged 18 to 99.
In order to determine the effectiveness of Sinopharm’s inactivated vaccine once morest the risk of developing a severe form of Covid-19, requiring hospitalization, case-control study was conducted between 1is February and June 30, 2021, with 348,190 adults aged 18 to 99. 140,892 of them had received two doses of the vaccine, 1,149 had received a booster dose and 206,149 were not vaccinated.
According to the authors of this study, the efficacy of Sinopharm’s inactivated vaccine was consistent with the results of phase III clinical trials. Two doses of this vaccine are therefore highly protective once morest severe or critical hospitalization associated with Covid-19 in 18-59 year olds and moderately effective in those over 60 years old.
According to these results, all the people who received a booster dose, the subject of this study, were not hospitalized, once morest 91 in the double vaccinated and 1,345 in the non-vaccinated. The booster dose should be assessed, the researchers say, given that it is highly recommended and used in Morocco and that it boosts immunity and limits hospitalizations.
In detail, the results of this study show that the unadjusted efficacy of the two-dose vaccination once morest serious or critical hospitalizations associated with Covid-19 was 90.2%. After adjusting for age, sex, etc., the two-dose protection once morest serious or critical hospitalization was 88.5%.
This two-dose adjusted protective efficacy in 18-60 year olds ranged from 93.9% to 100% and was 53.3% in adults 60 years and older. No serious or critical hospitalizations occurred among booster dose recipients, but there were too few booster dose recipients at the time of the study, the researchers report.
According to the authors of this study, the estimates of the protective efficacy of this vaccine are consistent with those of phase III clinical trials abroad. In Argentina, for example, the effectiveness of this two-dose vaccine was 84% in people aged ≥ 60 years. In a large cohort of healthcare workers in Peru, it was 50% once morest infection and 94% once morest Covid-19-related mortality.
In a study in Hungary with 895,000 vaccinated, two-dose protection was 69% once morest infection and 88% once morest Covid-19-related mortality. In the United Arab Emirates, a study conducted among people aged 15 and over showed that this vaccine reduced the risk of hospitalization by 79.8%.
